Collectively, these data established that CRC cells promote oxaliplatin resistance by modulating ARL4C ubiquitination through the ARL4C/RAP1/PI3K-Akt-mTOR signaling loop. This evidence concerns the gene ARL4C and colorectal carcinoma.